Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 19/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 19/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.62 |
| ▸ | HRH1 | P35367 | 2/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4935539 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL4943572 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL6355976 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL4935548 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL4942318 | 1.00 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3325386 | 0.89 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3327580 | 0.89 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3325001 | 0.89 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL3330275 | 0.89 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 | |
| SCHEMBL13299460 | 0.89 | SLC6A2 (0.56) | SLC6A2SLC6A4SLC6A3HRH1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | FISH PAUL VINCENT | 2008-07-03 | — | — | US | disclosed |
| EP-1744754-A1 | MORPHOLINE COMPOUNDS | Pfizer Limited (GB) | 2007-01-24 | — | — | EP | disclosed |
| WO-2005105100-A1 | MORPHOLINE COMPOUNDS | PFIZER LIMITED (GB) | 2005-11-10 | — | — | WO | disclosed |
| US-20050250775-A1 | Novel compounds | FISH PAUL V | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250775-A1 | Novel compounds | OPRL1, UGT1A1, NPSR1 | SLC6A2 133/4885SLC6A4 114/4885SLC6A3 104/4885 |
| US-20080161309-A1 | (2S)-2-[(1S)-(4-chloro-2-methoxyphenoxy)(pyridin-2-yl)methyl]morpholine; neuropathic pain, inflammatory pain, musculo-skeletal pain, central pain, heart and vascular pain, visceral pain, head pain or orofacial pain | OPRL1, MYLK2, TNNT2 | SLC6A2 201/4885SLC6A4 350/4885SLC6A3 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.